Donglin Yan

468 total citations
44 papers, 320 citations indexed

About

Donglin Yan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Donglin Yan has authored 44 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Donglin Yan's work include Prostate Cancer Treatment and Research (7 papers), PARP inhibition in cancer therapy (5 papers) and Lung Cancer Research Studies (5 papers). Donglin Yan is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), PARP inhibition in cancer therapy (5 papers) and Lung Cancer Research Studies (5 papers). Donglin Yan collaborates with scholars based in United States, China and Hong Kong. Donglin Yan's co-authors include Lingling Jiang, Lizhe Xie, Kang Li, Lan Ma, Mifang Yang, Jianwei Zhou, Zin Myint, Jill Kolesar, D. Otto and Aiping Li and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Donglin Yan

40 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donglin Yan United States 10 94 75 63 60 38 44 320
Jun-Ho Jang South Korea 13 213 2.3× 71 0.9× 132 2.1× 44 0.7× 5 0.1× 20 424
Tomoaki Hakariya Japan 10 98 1.0× 75 1.0× 88 1.4× 42 0.7× 6 0.2× 28 296
Yizhong Bao China 14 197 2.1× 42 0.6× 28 0.4× 32 0.5× 6 0.2× 37 605
Yusuke Mochizuki Japan 14 121 1.3× 24 0.3× 46 0.7× 34 0.6× 9 0.2× 41 456
Casey Pulliam United States 12 123 1.3× 26 0.3× 76 1.2× 46 0.8× 2 0.1× 24 338
Yuji Takahashi Japan 14 363 3.9× 73 1.0× 41 0.7× 72 1.2× 7 0.2× 26 567
Aaron A. Mehus United States 11 116 1.2× 25 0.3× 27 0.4× 31 0.5× 6 0.2× 22 337
Yunfei Chai United States 8 156 1.7× 71 0.9× 148 2.3× 53 0.9× 3 0.1× 8 430
Meriem Koual France 15 153 1.6× 149 2.0× 43 0.7× 108 1.8× 4 0.1× 48 659

Countries citing papers authored by Donglin Yan

Since Specialization
Citations

This map shows the geographic impact of Donglin Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donglin Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donglin Yan more than expected).

Fields of papers citing papers by Donglin Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donglin Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donglin Yan. The network helps show where Donglin Yan may publish in the future.

Co-authorship network of co-authors of Donglin Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Donglin Yan. A scholar is included among the top collaborators of Donglin Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donglin Yan. Donglin Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Connie D., J. Robert McCorkle, Derek B. Allison, et al.. (2025). M1 macrophage-engineered vesicles have anti-cancer activity in ovarian cancer. Cancer Nanotechnology. 16(1). 1 indexed citations
2.
Kim, Joon Kyung, Andrew James, Ravshan Burikhanov, et al.. (2025). Hydroxychloroquine effects on tumor suppressor PAR-4 levels in patients with oligometastatic prostate cancer: Results from a phase-2 trial.. Journal of Clinical Oncology. 43(5_suppl). 233–233. 1 indexed citations
3.
Gui, Laura, et al.. (2025). Magnetic-Responsive Material-Mediated Magnetic Stimulation for Tissue Engineering. Magnetochemistry. 11(10). 82–82. 1 indexed citations
4.
Myint, Zin, et al.. (2025). Organ perforation and fistula formation as adverse events in patients receiving tyrosine kinase inhibitors: A post-market analysis.. Journal of Clinical Oncology. 43(5_suppl). 528–528. 1 indexed citations
5.
Yan, Donglin, et al.. (2024). Phase I clinical trial designs in oncology: A systematic literature review from 2020 to 2022. Journal of Clinical and Translational Science. 8(1). e134–e134. 1 indexed citations
6.
Myint, Zin, William H. St. Clair, Stephen E. Strup, et al.. (2024). Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.. Journal of Clinical Oncology. 42(4_suppl). TPS350–TPS350.
7.
He, Zhichao, et al.. (2024). Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database. Therapeutic Innovation & Regulatory Science. 59(1). 135–141. 2 indexed citations
8.
Myint, Zin, William H. St. Clair, Stephen E. Strup, et al.. (2024). Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). TPS351–TPS351.
9.
Myint, Zin, William H. St. Clair, Stephen E. Strup, et al.. (2023). A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer. Cancers. 15(9). 2505–2505. 6 indexed citations
10.
11.
Kolesar, Jill, Donglin Yan, Zhonglin Hao, et al.. (2023). Abstract CT221: Phase II of frontline maintenance rucaparib in combination with nivolumab in ES SCLC. Cancer Research. 83(8_Supplement). CT221–CT221. 1 indexed citations
12.
13.
Myint, Zin, Riham El Khouli, Donglin Yan, et al.. (2022). A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases. BMC Cancer. 22(1). 415–415. 2 indexed citations
14.
Myint, Zin, Ramon C. Sun, Patrick J. Hensley, et al.. (2021). Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters. Cancers. 13(9). 2157–2157. 15 indexed citations
15.
Chauhan, Aman, Jill Kolesar, Donglin Yan, et al.. (2021). OA07.03 A Phase II Study of Frontline Rucaparib + Nivolumab in Platinum Sensitive ES SCLC: Interim Analysis. Journal of Thoracic Oncology. 16(10). S859–S859. 4 indexed citations
16.
Zhang, Xinyu, et al.. (2021). TERT Gene rs2736100 and rs2736098 Polymorphisms are Associated with Increased Cancer Risk: A Meta-Analysis. Biochemical Genetics. 60(1). 241–266. 10 indexed citations
17.
Wang, Qiang, Jianping Xiong, Xue Zhao, et al.. (2017). Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells. The International Journal of Biochemistry & Cell Biology. 92. 164–172. 25 indexed citations
18.
Patel, Reema, S. C. Maxwell, Donglin Yan, et al.. (2017). Medical oncologists’ perception of antiestrogen therapy benefit in premenopausal women with hormone receptor-positive early-stage breast cancer. Annals of Oncology. 29(3). 772–773. 1 indexed citations
19.
Zhao, Xiujuan, Jing‐Wei Xiong, Donglin Yan, et al.. (2017). JWA antagonizes paraquat-induced neurotoxicity via activation of Nrf2. Toxicology Letters. 277. 32–40. 25 indexed citations
20.
Yan, Donglin, Rosemarie L. Conigliaro, & Laura Fanucchi. (2016). Duly noted: Lessons from a two-site intervention to assess and improve the quality of clinical documentation in the electronic health record. Applied Clinical Informatics. 7(3). 653–659. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun-Ho Jang Breakdown of academic impact, for papers by Tomoaki Hakariya Breakdown of academic impact, for papers by Yizhong Bao Breakdown of academic impact, for papers by Yusuke Mochizuki Breakdown of academic impact, for papers by Casey Pulliam Breakdown of academic impact, for papers by Yuji Takahashi Breakdown of academic impact, for papers by Aaron A. Mehus Breakdown of academic impact, for papers by Yunfei Chai Breakdown of academic impact, for papers by Meriem Koual
Rankless by CCL
2026